Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Post by JDavenporton Mar 21, 2022 1:05am
338 Views
Post# 34530445

My Answer to beenthere's 2014 Question

My Answer to beenthere's 2014 Question
I understand your "2014" comment, beenthere.
 
The history goes something like this. The peptide comes out in 2014. Bioasis figures the peptide will help get some licensing deals done. Just over two years later, in late 2016, it's become obvious that deals aren't going to happen. Management figures new leadership might be helpful.
 
A few months later, in April 2017 a new leader is installed. It doesn't work out. The Prothena deal gets done but the money is way too low and it turns out that Prothena didn't have a drug that was worth advancing. No fault of Bioasis and xB3.
 
A few months after Prothena, things are bad and in March 2019, another leader is installed, DrDR. The company has to resort to bridge loans to hang on. In just over a year, in June 2020, the Chiesi deal happens and Bioasis is starting some preclinical programs and partnerships. That's where we're at now.
 
It's a long time from 2014, I agree, but each of the subsequent periods were quite short. Nothing was happening at Bioasis until DrDR got going and, really, she didn't get going until after Covid broke out, about a year after she became CEO.
 
About DrDR, I consider there to be weaknesses. Obviously there's a huge distance between her and shareholders. There is no IR that can handle any questions about the science, business opportunities or anything else of informational value. There is no production of promotional or informational material. I think DrDR wants to be the source of all information and she ain't talking much. I really dislike that part of Bioasis. 
 
But then, Bioasis needs accomplishments before it can actually talk about much of anything. DrDR has a lot of things going. The named companies, if not proof of much, are at least indicators of business and scientific activities.
 
I understand the damn 10-year problem. For me it's 11 years. For others as long as 14 years. But things only really got underway in H1 of 2020.
 
I think Bioasis needs to be left alone, but with a time limit, to get some stuff done. There are people on this forum who aren't willing to let that happen. That's the destructive world we live in. For some people, it's the only way to get noticed.
 
Sucks to have to deal with them but that's what it's like with everything - hate, tribalism, ignorance, the anonymity of social media - all creating idiot monsters who have no other influence on anything.
 
jd
<< Previous
Bullboard Posts
Next >>